Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Major breakout coming
Load up folks before the good news coming ..
A MUST BUY FOR BIOTECH INVESTORS
This Unknown low float Stock awaiting 5 FDA approvals .Cash burn is very low means they will be profitable very soon after first product launch .
Par Pharma (PRX) is the second largest Shareholder and Marketing Partner for Focalin which will be approved soon .
Market Cap of 47 Mil is really a BIG JOKE .They have enough cash to run their Company into profitable business .
I think $15++ is very realistic for 2011 .GL
Intellipharmaceutics (IPCI)
Market Cap: 47 M
Cash: 13 M
Price: 2.97 $
Shares Out: 15.9 M.. ( 8 Million shares held by CEO)
Monster Pipeline
http://www.intellipharmaceutics.com/pipeline.cfm
New Presentation ..CHECK IT OUT !!!
http://www.intellipharmaceutics.com/common/download/download.cfm?companyid=ABEA-43EQSZ&fileid=454112&filekey=1af962f6-fb75-40bb-8cad-70b77474e069&filename=2011%20IPCI%20Presentation%20Mar%2024%20for%20website.pdf
Intellipharmaceutics Submits 4th ANDA in 12 Months
http://www.pitchengine.com/proactivenewsroom/intellipharmaceutics-submits-4th-anda-in-12-months/108352/
Great Article ..A must READ
http://www.ibtimes.com/articles/94668/20101222/no-news-is-good-news-for-intellipharmaceutics-international-inc-ipci.htm
Another great Article
http://seekingalpha.com/instablog/643007-bio-tuesday/77860-intellipharmaceutics-ceo-moulded-at-biovail-u
Intellipharmaceutics now has five ANDAs awaiting FDA approval with reported sales for branded and generic versions of these products being approximately $8 billion in 2010. The Company develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway.
Intellipharmaceutics' development milestones for 2011 include the following:
Obtain FDA approval of our generic version of Focalin XR(R)
Have two additional ANDA applications accepted for filing by FDA
Establish at least one additional development/marketing alliance
Complete manufacturing of clinical batches of Rexista(TM) oxycodone
Initiate Phase I studies using clinical batches of Rexista(TM)oxycodone
Schedule a pre-IND meeting with FDA to discuss Rexista(TM) oxycodone clinical development plan
Buy now and you will be happy very soon
Upfront payment from upcoming Partnership for Duromist alone will be higher than current market cap of 13 million .
This is still a once in a lifetime opportunity .
Anything below 20c is a pure gift .
Buy all you can and sell later at much much higher price .
Next major Breakout in the making
Load up before its too late you will never see this low again.
My advice is BUY BUY BUY BUY
NVDL will be over 1$ minimum by year end
it was down because of capital raising thats all
No reason to sell this is time to load up all you can
We have 2 drugs launched in Feb 2011 means this company will be profitable soon
We have Duromist the Viagra oral spray which has monster potential once approved
We awaiting Partnership for Duro which will bring a lot of upfront $$ to NVDl
We could see 2-3$ easily with all these upcoming news
Better to be in before the real jump coming
Partnership coming any time now
Rally continues WOOOHOOOOO
A lifetime Opportunity here Folks
Why NVDL is a SUPER MUST BUY // READ
This is the perfect time to buy or add more shares of this undiscovered Stock .Im sure that Shareholders will be very very happy in the near future .Looking to add another 250k-500k shares next Week .
Good Potential here to see 3-5$ with FDA approval for Viagra Spray which will be the only on the Multi-Billion Dollar Market .GLTA
Market Cap 5.64 M
Price: 0.049 $
Pipeline
http://www.novadel.com/pipeline/duromist.htm
Presentation
http://www.novadel.com/pdf/CorporatePresentation.pdf
Zolpimist (Insomnia) launched in Feb 2011 = 1.5 Billion Dollar Market Size
http://www.wsw.com/webcast/roth24/nvd/2__Slide7.JPG
Nitromist (Angina) launched in Jan 2011 = 200 Million Dollar Market Size
http://www.wsw.com/webcast/roth24/nvd/2__Slide10.JPG
Duromist (Erectile Dysfunction) NDA Approval in 2012 = Multi-Billion Dollar Market
http://www.wsw.com/webcast/roth24/nvd/2__Slide14.JPG
http://www.wsw.com/webcast/roth24/nvd/2__Slide13.JPG
http://www.wsw.com/webcast/roth24/nvd/2__Slide21.JPG
Duromist™ (Viagra Spray) Development Plan
•2011 - Marketing agreement for Duromist
•2011 – Complete PK based clinical trials and file NDA
•2012 – NDA approval
RALLLYYYYYYYYYYYYYYYy
10c +++ next watch and learn freaks lol
Here is the next Winner which is wayyyy undervalued . 2 Great Products launched in 1Q 2011 means the Company now starts making money .
Market cap of less that 5 Million is really a Big Joke . Duromist is the GAME CHANGER for Novadel NDA filing is planned for 4Q 2011.They have enough cash for 1 year excluding Upfront Payments from upcoming Partnership .
Do your due Diligence and then load up the Truck .GL
Novadel (NVDL.OB)
Market Cap : 4.6 M
Cash : 1.6 M
Price: 0.04 $
Partnership for Duromist in 1H 2011
NDA filing for Duromist for the treatment of erectile dysfunction in 4Q 2011
In January 2011, NitroMist for the treatment of angina was launched in the U.S. by our marketing partner Akrimax Pharmaceuticals.
In February 2011, Zolpimist for the treatment of insomnia was launched in the U.S. by our marketing partner ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal.
We successfully completed our pilot PK study for Duromist™, our sildenefil oral spray product, and are moving forward with a clinical program with an anticipated filing of an NDA by the end of 2011.
“Our 2010 results represent an improvement over the prior year results. We ended 2010 with a modest amount of cash, however this amount was buttressed in the first quarter of 2011 by a milestone payment from a licensee, a grant from the U.S. government, and a capital raise. In addition, our licensees launched our NitroMist® and Zolpimist™ products in early 2011. We believe NitroMist and Zolpimist will be well accepted in the marketplace, and we anticipate the initiation of royalty revenue in 2011,” remarked Steven B. Ratoff, our Chairman and CEO. “We believe our efforts provide a foundation for the further development of our product pipeline and we will continue to progress the development of Duromist as well as control our costs during 2011.”
Recent Accomplishments
In January 2011, we received a $500,000 milestone payment from Akrimax Pharmaceuticals.
In January 2011, NitroMist was launched in the U.S. by our marketing partner Akrimax Pharmaceuticals.
In February 2011, Zolpimist was launched in the U.S. by our marketing partner ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal.
In February 2011, we received $244,479 for the grant awarded in 2010 under the IRS’ Qualifying Therapeutic Discovery Project program.
In February 2011, we received gross proceeds of $1.6 million from the sale of 1,667 shares of our preferred stock.
RALLYYYYY CONTINUES
BETTER LOAD UP BEFORE ITS TOO LATE WE ARE STILL TRADING WAYY BELOW CASH
run will continue
great buying opp
Pullback creates a great buying opp
Last chance to buy below 1$ ...
1 Dollar coming ladies and gentlemen
Cash per share 1.10
Still very very cheap
Another good day ahead ..Still a fantastic opportunity
Load up or miss the Monster Opportunity
She is flying again and still trading below cash
TLON is on track to hit 1 dollar .Still very very cheap
Consolidation creates a great buying opportunity
Runup will continue today ...
Still trading wayyyy below cash
Still trading below cash
Great buying opp again
Breakout in the making
Still a Fantastic buying opportunity
Neurogesx (NGSX)
Market Cap: 70 M
Cash: 57.7 M
Price: 4
Shares Out: 17.7 M // 14 M are in strong hands
Float : 4 M
Dr. Juan Sanchez, an analyst at Punk Ziegel Healthcare Group, says Qutenza could be widely adopted as a treatment for chronic peripheral neuropathic pain conditions, and as such it has an opportunity to be a $300 million product in the U.S. and generate sales of $175 million in Europe. The FDA's approval of Qutenza was the first in 10 years for a prescription-strength topical treatment of pain from post-herpetic neuralgia (PHN). Neuralgia is the nerve pain that occurs with shingles. Every year about 1 million Americans develop shingles, a painful viral infection caused by reactivation of a virus that causes chickenpox !
NeurogesX announced plans to submit a sNDA for Qutenza in the first half of 2011 for the treatment of HIV-associated neuropathy (HIV-AN) .Qutenza, which currently has U.S. orphan drug designation and fast track status, may be eligible for six-month priority review. Qutenza has Blockbuster Potential in this new HIV indication !
Stock exploding yippiiiiiiiiiiiiiii
Load up the truck before its too late
THERE ARE MANY REASONS TO INVEST IN THIS SLEEPING LOW FLOAT GIANT .A LOT OF MAJOR NEWS COMING VERY SOON TO PUSH THIS LOW FLOAT MONSTER TO NEW HIGHS .
1.) Most Big Investors paying more than $6 per share
2.) NGSX is trading near Cash Level
3.) First Class Partnership with Astellas for European Market
4.) Attractive Takeover Candidate
5.) Very low float // Only 4 M on the float
6.) Very Strong Shareholder which owns 80% of 17 M Shares Outstanding
7.) Unique Pain Patch supported with strong Patents
8.) Qutenza could be the first approved treatment for HIV-AN
9.) Qutenza has Orphan Drug Status
10.) New Asia/Latin America PartnerShip with Upfront Payments in 1H11
11.) Submit sNDA for HIV-AN indication in 2Q
12.) Acceptance of sNDA + Priority Review by FDA in 3Q11
13.) FDA approval for Qutenza (HIV-AN) in 4Q11
Some Slides from Roth Presetation
http://www.wsw.com/webcast/roth24/tt/2__Slide13.JPG
http://www.wsw.com/webcast/roth24/tt/2__Slide3.JPG
http://www.wsw.com/webcast/roth24/tt/2__Slide9.JPG
http://www.wsw.com/webcast/roth24/tt/2__Slide14.JPG
GREAT Pipeline
http://www.wsw.com/webcast/roth24/tt/2__Slide19.JPG
Submit NDA for Marqibo in 2Q11 << CONFIRMED AGAIN IN THIS NEW PRESENTATION
http://www.wsw.com/webcast/roth24/tt/2__Slide20.JPG
THIS IS THE NEXT BIG MONSTER STOCK ..READ WHY
This is a real unknown gem ,once investors discover this stock it will explode like a nuclear bomb .LOAD UP THE TRUCK WHILE YOU STILL CAN BECAUSE ITS TRADING SIGNIFCANTLY BELOW CASH LEVEL !!
NDA filing for Blockbuster Marqibo next quarter and it could be approved before the end of this Year .
MARKET CAP OF 10 MILLION MAKES ME A BIG LAUGH // TLON WILL MOVE INTO DOUBLE DIGITS IN THE COMING MONTHS (As an example 10$ per share means 270 Mil Market Cap even at 10$ A BIG JOKE !!
Talon Therapeutics (TLON.OB)
Market Cap: $10,4 Mil
Cash: 27,2 Mil
Price : 0.48 $
Shares Out: 21,2 Mil
New Presentation // A MUST READ !!
http://www.talontx.com/pdf/talontx_corp_pres.pdf
Marqibo® is poised for accelerated approval in 4Q 2011
NDA submission and request for priority revue expected in 2Q 2011
Sought indica<on =Adult Ph(--)ALL in 2nd relapse or that has failed 2lines of Rx
35% overall response rate as 3rd-6th line treatment in RALLY study
20% complete response rate with impressive median dura<on and survival
.................
http://biotuesdays.com/2011/02/01/talon-to-seek-accelerated-approval-of-marqibo/
Talon Therapeutics (OTCBB:TLON) plans to submit a new drug application with the FDA for priority review of its Marqibo oncology drug in the second quarter this year and is hoping for accelerated approval in the final quarter of the year.
“We are seeking accelerated approval based on data from our Phase 2 RALLY study where we demonstrated a 35% overall response rate using single agent Marqibo as third, fourth, fifth or sixth line treatment,” CEO Dr. Steven Deitcher says in an exclusive interview with BioTuesdays.com. “This is the most heavily pretreated and advanced Acute Lymphoblastic Leukemia (ALL) population that has ever been described or studied in the literature.”
If Marqibo is cleared by the FDA for use in additional, larger indications, Talon is looking at a multibillion-dollar potential
Great buying opportunity
HEY FOLKS THERE IS NO BETTER PLAY THAN TLON OUT THERE
RALLLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY
1$+++ coming
We closed above $4 which is a good sign .Earnings coming on Monday i expect good news so i think we will see 5-6 dollar quickly in the coming days .Still a huge buying opportunity .GL
http://www.traderscreener.com/stocks/nasdaq-NGSX.aspx
NASDAQ:NGSX Technical Analysis
NASDAQ:NGSX - NeurogesX, Inc.
NGSX - Sector: Healthcare, Industry: Healthcare Facilities.
NGSX is currently trading in a positive uptrend with more buyers than sellers.
NGSX gained 1.52% on 03/24/11 and a total percentage of 28.42% in the past 5 day
NGSX is trading in the range of $3.12 - $5.80 in the past 30 days.
Money Flow Index (MFI) is bullish and moving up for NGSX.
The 10-day simple moving average is bullish and moving up for NGSX.
Average Trading Volume: Up Over 10%.
Commodity Channel Index (CCI) is bullish for NGSX.
Stock Performance on Mondays in the past 90 days: 8.83%
Stock Performance on Tuesdays in the past 90 days: -32.41%
Stock Performance on Wednesdays in the past 90 days: -21.53%
Stock Performance on Thursdays in the past 90 days: -13.53%
Stock Performance on Fridays in the past 90 days: 8.77%
Next Earnings Release Date: 03/28/11.
Stock Rating: Buy with a score of 4/5.
THIS IS THE NEXT BIG MONSTER STOCK ..READ WHY
This is a real unknown gem ,once investors discover this stock it will explode like a nuclear bomb .LOAD UP THE TRUCK WHILE YOU STILL CAN BECAUSE ITS TRADING SIGNIFCANTLY BELOW CASH LEVEL !!
NDA filing for Blockbuster Marqibo next quarter and it could be approved before the end of this Year .
MARKET CAP OF 10 MILLION MAKES ME A BIG LAUGH // TLON WILL MOVE INTO DOUBLE DIGITS IN THE COMING MONTHS (As an example 10$ per share means 270 Mil Market Cap even at 10$ A BIG JOKE !!
Talon Therapeutics (TLON.OB)
Market Cap: $10,4 Mil
Cash: 27,2 Mil
Price : 0.48 $
Shares Out: 21,2 Mil
New Presentation // A MUST READ !!
http://www.talontx.com/pdf/talontx_corp_pres.pdf
Marqibo® is poised for accelerated approval in 4Q 2011
NDA submission and request for priority revue expected in 2Q 2011
Sought indica<on =Adult Ph(--)ALL in 2nd relapse or that has failed 2lines of Rx
35% overall response rate as 3rd-6th line treatment in RALLY study
20% complete response rate with impressive median dura<on and survival
.................
http://biotuesdays.com/2011/02/01/talon-to-seek-accelerated-approval-of-marqibo/
Talon Therapeutics (OTCBB:TLON) plans to submit a new drug application with the FDA for priority review of its Marqibo oncology drug in the second quarter this year and is hoping for accelerated approval in the final quarter of the year.
“We are seeking accelerated approval based on data from our Phase 2 RALLY study where we demonstrated a 35% overall response rate using single agent Marqibo as third, fourth, fifth or sixth line treatment,” CEO Dr. Steven Deitcher says in an exclusive interview with BioTuesdays.com. “This is the most heavily pretreated and advanced Acute Lymphoblastic Leukemia (ALL) population that has ever been described or studied in the literature.”
If Marqibo is cleared by the FDA for use in additional, larger indications, Talon is looking at a multibillion-dollar potential
market makers manipulating this stock to grab more cheap shares .
Great buying opportunity.